H Zheng1,2, L Xie3, M Zhan1, F Wen4, T Xu5, Q Li6,7. 1. Department of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, China. 2. West China Biostatistics and Cost-Benefit Analysis Center, Sichuan University, Chengdu, China. 3. Department of the Infrastructure, West China Hospital, Sichuan University, Chengdu, China. 4. Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. 5. Department of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, China. fbqiu@163.com. 6. West China Biostatistics and Cost-Benefit Analysis Center, Sichuan University, Chengdu, China. keythera@126.com. 7. Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. keythera@126.com.
Abstract
BACKGROUND: The BEYOND trial found that the addition of bevacizumab (B) to paclitaxel-carboplatin (PC) chemotherapy provided a significant clinical benefit to Chinese patients with metastatic non-squamous non-small-cell lung cancer (NSCLC). This study aimed to evaluate the cost-effectiveness of adding B to first-line PC induction and continuation maintenance therapy from a Chinese perspective. METHODS: A Markov model was developed to estimate the cost and effectiveness of B + PC in the induction and maintenance therapy of patients with metastatic non-squamous NSCLC. Costs were calculated in the Chinese setting, and health outcomes derived from the BEYOND trial were measured as quality-adjusted life years (QALYs). A one-way sensitivity analysis was conducted to explore the impact of various parameters in the study. RESULTS: The B + PC treatment was more costly ($112,943.40 versus $32,171.43) and more effective (1.07 QALYs versus 0.80 QALYs) compared with the PC treatment. Adding B to the PC regimen for non-squamous NSCLC results in an incremental cost-effectiveness ratio of $299,155.44 per QALY, which exceeded the accepted societal willingness-to-pay threshold ($23,970.00) for China. In the sensitivity analysis, the duration of progression-free survival (PFS) for the B + PC group, the cost of the PFS state for B + PC group and the price of B were considered the most sensitive factors in the model. CONCLUSIONS: The addition of B to first-line PC induction and maintenance therapy was not determined to be a cost-effective strategy for metastatic non-squamous NSCLC in China, even when an assistance program was provided.
BACKGROUND: The BEYOND trial found that the addition of bevacizumab (B) to paclitaxel-carboplatin (PC) chemotherapy provided a significant clinical benefit to Chinese patients with metastatic non-squamous non-small-cell lung cancer (NSCLC). This study aimed to evaluate the cost-effectiveness of adding B to first-line PC induction and continuation maintenance therapy from a Chinese perspective. METHODS: A Markov model was developed to estimate the cost and effectiveness of B + PC in the induction and maintenance therapy of patients with metastatic non-squamous NSCLC. Costs were calculated in the Chinese setting, and health outcomes derived from the BEYOND trial were measured as quality-adjusted life years (QALYs). A one-way sensitivity analysis was conducted to explore the impact of various parameters in the study. RESULTS: The B + PC treatment was more costly ($112,943.40 versus $32,171.43) and more effective (1.07 QALYs versus 0.80 QALYs) compared with the PC treatment. Adding B to the PC regimen for non-squamous NSCLC results in an incremental cost-effectiveness ratio of $299,155.44 per QALY, which exceeded the accepted societal willingness-to-pay threshold ($23,970.00) for China. In the sensitivity analysis, the duration of progression-free survival (PFS) for the B + PC group, the cost of the PFS state for B + PC group and the price of B were considered the most sensitive factors in the model. CONCLUSIONS: The addition of B to first-line PC induction and maintenance therapy was not determined to be a cost-effective strategy for metastatic non-squamous NSCLC in China, even when an assistance program was provided.
Entities:
Keywords:
Cost-effectiveness; Induction and maintenance therapy; Metastatic non-small-cell lung cancer
Authors: Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares Journal: Lancet Oncol Date: 2012-01-26 Impact factor: 41.316
Authors: Cesare Gridelli; Filippo de Marinis; Massimo Di Maio; Andrea Ardizzoni; Chandra P Belani; Federico Cappuzzo; Fortunato Ciardiello; Panagiotis Fidias; Luis Paz-Ares; Francesco Perrone; Robert Pirker; Luigi De Petris; Rolf Stahel Journal: Lung Cancer Date: 2012-01-21 Impact factor: 5.705
Authors: Jie Ting; PharmD Tien Ho; Pin Xiang; Amanda Sugay; Maher Abdel-Sattar; Leslie Wilson Journal: Value Health Date: 2015-06-22 Impact factor: 5.725
Authors: Konstantin J Dedes; Klazien Matter-Walstra; Matthias Schwenkglenks; Bernhard C Pestalozzi; Daniel Fink; Peter Brauchli; Thomas D Szucs Journal: Eur J Cancer Date: 2009-01-13 Impact factor: 9.162
Authors: John K Chan; Thomas J Herzog; Lilian Hu; Bradley J Monk; Tuyen Kiet; Kevin Blansit; Daniel S Kapp; Xinhua Yu Journal: Oncologist Date: 2014-04-10
Authors: Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler Journal: J Clin Oncol Date: 2013-07-01 Impact factor: 44.544
Authors: Kimberly B Shepard; David T Vodak; Philip J Kuehl; David Revelli; Yue Zhou; Amanda M Pluntze; Molly S Adam; Julia C Oddo; Lauren Switala; Jonathan L Cape; John M Baumann; Michael Banks Journal: AAPS PharmSciTech Date: 2021-08-31 Impact factor: 3.246
Authors: Ning Wan; Tian-Tian Zhang; Si-Hua Hua; Zi-Luo Lu; Bo Ji; Li-Xia Li; Li-Qing Lu; Wen-Jie Huang; Jie Jiang; Jian Li Journal: Cancer Med Date: 2020-01-16 Impact factor: 4.452